RAD51C Antibody

1. results increase our knowledge about the RAD51C and RAD51D mutation spectrum and support the notion that these genes should be included in the gene panel testing performed on patients with hereditary breast and ovarian cancer syndrome PMID: 29409816
2. The authors assessed whether RAD51C promoter hypermethylation like mutation was associated with increased survival or increased sensitivity to platinum chemotherapy. However the results showed that neither outcomes were met PMID: 29233532
3. novel splice-site mutations affect the last nucleotide of exon 2 (c.404G>C, c.404G>T) and disrupt proper RAD51C pre-mRNA processing. PMID: 27622768
4. We showed that the mutation frequency of RAD51C in Japanese familial breast cancer cases was similar to that in Western countries and that the prevalence of deleterious mutation of PALB2 was possibly lower. Furthermore, our results suggested that BRIP1 mutation frequency in Japan might differ from that in Western countries PMID: 28796317
5. Here we report yet another example of a rare RAD51C missense change (p.Arg312Trp) that impairs protein function. PMID: 28829762
6. Using the human mammary epithelial cell line MCF10A, we show that deletion of TP53 can rescue RAD51C-deficient cells from radiation-induced cellular senescence, whereas it exacerbates their centrosome amplification and nuclear abnormalities PMID: 26820992
7. Results identified a chromosomal translocation between Rad51C and Ataxin-7 in colorectal tumors. The in-frame fusion transcript results in a fusion protein with molecular weight of 110 KDa. In vitro 5-Azacytidine treatment of colorectal tumor cells showed expression of the fusion gene is regulated by promoter methylation. PMID: 27296891
8. Germline mutation in RAD51C gene is associated with neoadjuvant therapy response in triple negative breast patients. PMID: 27328445
9. Germline RAD51C mutation was found in patients with hereditary and sporadic gastric cancer. PMID: 28024868
10. individuals with mutations in RAD51C that are exposed to estrogen would be more susceptible to accumulation of DNA damage, leading to cancer progression. PMID: 27753535
11. Overexpression of RAD51C is associated with resistance to cisplatin and radiation in non-small cell lung cancer. PMID: 27465554
12. RAD51C mutations were identified in 0.5 % of Danish families. PMID: 26740214
13. RAD51C mutation is not associated with high-risk patients from Serbian hereditary breast/ovarian cancer. PMID: 26406419
14. a mutation analysis in 171 high-risk BRCA1 and BRCA2 negative ovarian cancer patients, to evaluate the frequency of hereditary RAD51C and RAD51D variants in Czech population, is reported. PMID: 26057125
15. Novel Rad51C splice variants occur in colorectal tumors and cells: Variant 1 without exon-7, Variant 2 without exon 6 and 7 , or Variant 3 without exon 7 and 8. They are associated with FANCD2 foci positive colorectal tumors and microsatellite stability. PMID: 25669972
16. conclude that the woman has two potential disease-causing mutations and that predictive testing of family members should include both the RAD51C and BRCA2 mutation PMID: 25154786
17. RAD51C and RAD51D are moderate ovarian cancer susceptibility genes. PMID: 26261251
18. RAD51C mutation is associated with breast and ovarian cancer. PMID: 25086635
19. The effect of common single nucleotide polymorphisms (SNPs) in non-coding regions of RAD51C in modulating the risk of breast cancer was investigated. PMID: 25343521
20. Mutations in RAD51C are associated with drug resistance in breast cancer. PMID: 25292178
21. the Rad51C promoter fragment can be used to transcriptionally target cancer cells. PMID: 24742710
22. The findings suggest that RAD51C plays a marginal role in breast and ovarian cancer predisposition in Pakistan. PMID: 24800917
23. three different cancer susceptibility and FA proteins function in a DNA repair pathway based upon the PALB2 WD40 domain binding to RAD51C and BRCA2. PMID: 24141787
24. Paralogs of RAD51 might be candidates for genetic risk factors in sporadic squamous cell carcinomas of the head and neck. PMID: 24315737
25. Single nucleotide polymorphisms in the Rad51C gene are strongly associated with increased risk for developing head and neck cancer. PMID: 24631219
26. RAD51C-deficient cancer cells are highly sensitive to olaparib and offer preclinical proof-of-principle that RAD51C deficiency may be considered a biomarker for predicting the antitumor effects of olaparib. PMID: 23512992
27. RAD51C is a susceptibility gene for ovarian and BC. PMID: 22725699
28. Study observed centrosome defects in the absence of XRCC3. While RAD51B and RAD51C act early in homologous recombination, XRCC3 functions jointly with GEN1 later in the pathway at the stage of Holliday junction resolution. PMID: 23108668
29. No RAD51C mutations c.837 + 1G > A or c.93delG were detected. PMID: 23176254
30. This study concludes that germline mutations in RAD51C contribute marginally to breast and ovarian cancer susceptibility in ethnically diverse, Jewish high risk families. PMID: 23117857
31. RAD51C mutations are rare events among high-risk breast cancer and breast/ovarian cancer families. PMID: 22476429
32. We propose that analogous to germline genetic mutations constitutive epimutations in BRCA1 and RAD51C may serve as the first hit of tumor development. PMID: 22843497
33. study detected 1.3 percent mutations of RAD51C in breast and ovarian cancer families, while mutations in breast cancer only families seem to be very rare PMID: 22451500
34. the contribution of RAD51C and RAD51D gene mutations to an inherited high risk of ovarian cancer is very small PMID: 22752287
35. RAD51C germline mutations in families with a history for both breast and ovarian cancer appear to have a low prevalence with the exception of some founder mutations. PMID: 22370629
36. Missense variant of RAD51C (p.Gly264Ser) is a moderate penetrance allele in high-risk breast and ovarian cancer families. PMID: 21990120
37. unravel the critical role of RAD51C in the FA pathway of ICL repair and as a tumor suppressor. PMID: 22167183
38. RAD51C mutations are implicated in breast and ovarian cancer predisposition. PMID: 21750962
39. RAD51C is a rare breast and ovarian cancer susceptibility gene. PMID: 21980511
40. PALB2 mutations are present in a small but substantial proportion of inherited breast cancer cases, and indicates that RAD51C at a population level does not account for a substantial number of familial breast cancer cases PMID: 21409391
41. These results suggest RAD51C as the first moderate-to-high risk susceptibility gene for ovarian cancer. PMID: 21616938
42. Data show there was no deleterious RAD51C mutation among the 454 familial breast/ovarian cancer patients. PMID: 20723205
43. Unable to confirm the contribution of the RAD51C gene to hereditary breast and ovarian cancer. PMID: 20697805
44. Reports show RAD51C is a cancer susceptibility gene associated with increased risk of Fanconi anemia-like disorder, breast and ovarian cancer.[Review] PMID: 20952512
45. biallelic germline mutations in a RAD51 paralog are associated with an FA-like syndrome [case report] PMID: 20400963
46. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene PMID: 20400964
47. This work describes the in vitro and in vivo identification of the RAD51B/RAD51C heterocomplex PMID: 11744692
48. Rad51B and Rad51C function through interactions with the human Rad51 recombinase and play a crucial role in the homologous recombinational repair pathway PMID: 12427746
49. analysis of protein domains important for functioning of RAD51L2; there is a specific requirement for RAD51L2 in gene conversion in mammalian cells PMID: 12966089
50. a fragment of Rad51B containing amino acid residues 1-75 interacts with the C-terminus and linker of Rad51C, residues 79-376, and this region of Rad51C also interacts with mRad51D and Xrcc3 PMID: 14704354

Show More

Hide All

HGNC: 9820

OMIM: 602774

KEGG: hsa:5889

STRING: 9606.ENSP00000336701

UniGene: Hs.412587